Chinook Therapeutics Investor Relations Material

Chinook Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's pipeline targets rare, severe chronic kidney conditions, aiming to address unmet medical needs in areas such as immunoglobulin A (IgA) nephropathy and other forms of glomerular diseases. Chinook leverages advanced research technologies and a deep understanding of kidney biology to develop innovative therapies designed to slow or prevent disease progression. The company is headquartered in Seattle, Washington, and its shares are listed on the Nasdaq.